{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:12:28Z","timestamp":1791637948276,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-03985-9","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T15:18:17Z","timestamp":1739027897000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Finerenone in the management of diabetes kidney disease"],"prefix":"10.1186","volume":"26","author":[{"given":"Parijat","family":"De","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May T","family":"Khine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Frankel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Goldet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasish","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa M","family":"Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahseen A","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Fogarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janaka","family":"Karalliedde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritwika","family":"Mallik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipesh C","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Wahba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Winocour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagen","family":"Zac-Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Bain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Bellary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indranil","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"issue":"2","key":"3985_CR1","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2012070718","volume":"24","author":"M Afkarian","year":"2013","unstructured":"Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, de Boer IH. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302\u20138. https:\/\/doi.org\/10.1681\/ASN.2012070718.","journal-title":"J Am Soc Nephrol"},{"key":"3985_CR2","unstructured":"UK Renal Registry. (2022) UK Renal Registry 24th Annual Report\u2013 data to 31\/12\/2020, Bristol, UK. Available from https:\/\/ukkidney.org\/audit-research\/annual-report"},{"key":"3985_CR3","unstructured":"Survey for England. 2018 - NatCen publication website (Link: http:\/\/healthsurvey.hscic.gov.uk\/support-guidance\/publichealth\/health-survey-for-england-2018.aspx)"},{"key":"3985_CR4","doi-asserted-by":"publisher","unstructured":"Cea Soriano L, Johansson S, Stefansson B, Garc\u00eda Rodr\u00edguez, Al, et al. Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors. Cardiovasc Diabetol. 2015. https:\/\/doi.org\/10.1186\/s12933-015-0204-5.","DOI":"10.1186\/s12933-015-0204-5"},{"issue":"8","key":"3985_CR5","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.2337\/dc20-0352","volume":"43","author":"JI Morton","year":"2020","unstructured":"Morton JI, Liew D, McDonald SP, Shaw JE, Magliano DJ. The association between age of onset of type 2 diabetes and the long-term risk of end-stage kidney disease: a national registry study. Diabetes Care. 2020;43(8):1788\u201395. https:\/\/doi.org\/10.2337\/dc20-0352.","journal-title":"Diabetes Care"},{"issue":"4","key":"3985_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11606-010-1511-x","volume":"26","author":"LS Dalrymple","year":"2011","unstructured":"Dalrymple LS, Katz R, Kestenbaum B, Shlipak MG, Sarnak MJ, Stehman-Breen C, et al. Chronic kidney disease and the risk of end-stage renal disease versus death. J Gen Intern Med. 2011;26(4):379\u201385. https:\/\/doi.org\/10.1007\/s11606-010-1511-x.","journal-title":"J Gen Intern Med"},{"key":"3985_CR7","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WK, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861\u20139. https:\/\/doi.org\/10.1056\/NEJMoa011161.","journal-title":"N Engl J Med"},{"issue":"4","key":"3985_CR8","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.ekir.2022.01.004","volume":"7","author":"D Banerjee","year":"2022","unstructured":"Banerjee D, Winocour P, Chowdhury TA, De P, Wahba M, Montero R, Fogarty D, Frankel A, Goldet G, Karalliedde J, et al. Management of hypertension in patients with Diabetic kidney disease: Summary of the Joint Association of British Clinical Diabetologists and UK kidney Association (ABCD-UKKA) Guideline 2021. Kidney Int Rep. 2022;7(4):681\u20137. https:\/\/doi.org\/10.1016\/j.ekir.2022.01.004.","journal-title":"Kidney Int Rep"},{"key":"3985_CR9","unstructured":"Mark PB, Winocour P. ABCD-Renal Association Clinical Practice Guidelines for management of lipids in adults with diabetes mellitus and nephropathy and\/or chronic kidney disease. 2017. www.diabetologistsabcd.org.uk and www.renal.org"},{"issue":"24","key":"3985_CR10","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med"},{"issue":"15","key":"3985_CR11","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"key":"3985_CR12","doi-asserted-by":"publisher","unstructured":"Empagliflozin in Patients with Chronic Kidney Disease. The EMPA-KIDNEY Collaborative Group. January 12, 2023. N Engl J Med. 2023; 388:117\u2013127. https:\/\/doi.org\/10.1056\/NEJMoa2204233","DOI":"10.1056\/NEJMoa2204233"},{"key":"3985_CR13","first-page":"8892","volume":"49","author":"H Selye","year":"1943","unstructured":"Selye H, Hall CE, Rowley EM. Malignant hypertension produced by treatment with desoxycorticosterone acetate and Sodium Chloride. Can Med Assoc J. 1943;49:8892.","journal-title":"Can Med Assoc J"},{"issue":"10","key":"3985_CR14","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341(10):709\u201317. https:\/\/doi.org\/10.1056\/NEJM199909023411001.","journal-title":"N Engl J Med"},{"issue":"15","key":"3985_CR15","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1313731.","journal-title":"N Engl J Med"},{"issue":"1","key":"3985_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1009492.","journal-title":"N Engl J Med"},{"issue":"31","key":"3985_CR17","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim SY, Zannad F. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453\u201363. https:\/\/doi.org\/10.1093\/eurheartj\/eht187.","journal-title":"Eur Heart J"},{"issue":"27","key":"3985_CR18","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"G Filippatos","year":"2016","unstructured":"Filippatos G, Anker SD, Bohm M, Gheorghiade M, Kober L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, et al. A randomized controlled study of Finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J. 2016;37(27):2105\u201314. https:\/\/doi.org\/10.1093\/eurheartj\/ehw132.","journal-title":"Eur Heart J"},{"issue":"23","key":"3985_CR19","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, et al. Effect of Finerenone on chronic kidney Disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2025845.","journal-title":"N Engl J Med"},{"key":"3985_CR20","doi-asserted-by":"publisher","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. The New England journal of medicine 2021. https:\/\/doi.org\/10.1056\/NEJMoa2110956","DOI":"10.1056\/NEJMoa2110956"},{"issue":"6","key":"3985_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","volume":"145","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL, Tasto C, Joseph A, Kolkhof P, Lage A, et al. Finerenone reduces risk of Incident Heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD Trial. Circulation. 2022;145(6):437\u201347. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.057983.","journal-title":"Circulation"},{"issue":"6","key":"3985_CR22","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, et al. Cardiovascular and kidney outcomes with Finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474\u201384. https:\/\/doi.org\/10.1093\/eurheartj\/ehab777.","journal-title":"Eur Heart J"},{"key":"3985_CR23","unstructured":"Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants with Heart Failure and Chronic Kidney Disease. A phase 2b, Randomized, Double-Blind, active controlled, Multi Centre Study to evaluate the efficacy, safety and tolerability of oral AZD9977 and Dapagliflozin Treatment in patients with heart failure and chronic kidney disease (US clinical trials Registry\u2013 sponsor Astra Zeneca). Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in participants with heart failure and Chronic Kidney Disease (astrazenecaclinicaltrials.com)."},{"issue":"1","key":"3985_CR24","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","volume":"33","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Joseph A, Anker SD, Filippatos G, Rossing P, Ruilope LM, Pitt B, Kolkhof P, Scott C, Lawatscheck R, Wilson DJ, Bakris GL. FIDELIO-DKD investigators. Hyperkalemia Risk with Finerenone: results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022;33(1):225\u201337. https:\/\/doi.org\/10.1681\/ASN.2021070942. Epub 2021 Nov 3. PMID: 34732509; PMCID: PMC8763180.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"3985_CR25","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/ndt\/gfac198","volume":"38","author":"JB Green","year":"2023","unstructured":"Green JB, Mottl AK, Bakris G, Heerspink HJL, Mann JFE, McGill JB, Nangaku M, Rossing P, Scott C, Gay A, Agarwal R. Design of the COmbinatioN effect of Finerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrol Dial Transpl. 2023;38(4):894\u2013903. https:\/\/doi.org\/10.1093\/ndt\/gfac198. PMID: 35700142; PMCID: PMC10064838.","journal-title":"Nephrol Dial Transpl"},{"key":"3985_CR26","unstructured":"National Institute for Health and Care Exellence. Finerenone for treating chronic kidney disease in type 2 diabetes. NICE technology appraisal guidance, reference number: TA877 published: 23 March 2023 https:\/\/www.nice.org.uk\/guidance\/ta877"},{"key":"3985_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12882-021-02587-5","volume":"23","author":"D Banerjee","year":"2022","unstructured":"Banerjee D, Winocour P, Chowdhury TA, et al. Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021. BMC Nephrol. 2022;23:9. https:\/\/doi.org\/10.1186\/s12882-021-02587-5.","journal-title":"BMC Nephrol"},{"key":"3985_CR28","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98(4S):S1-S115. https:\/\/doi.org\/10.1016\/j.kint.2020.06.019. PMID: 32998798. doi: 10.1016\/j.kint.2020.06.019.","DOI":"10.1016\/j.kint.2020.06.019"},{"key":"3985_CR29","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and Risk Management: Standards of Care in Diabetes\u20142024. Diabetes Care 2024 Jan 1; 47 (Supplement 1): S179-S218. https:\/\/doi.org\/10.2337\/dc24-S010","DOI":"10.2337\/dc24-S010"},{"issue":"16","key":"3985_CR30","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Pi\u00f1a IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M. EMPEROR-Preserved Trial investigators. Empagliflozin in Heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2107038. Epub 2021 Aug 27. PMID: 34449189.","journal-title":"N Engl J Med"},{"key":"3985_CR31","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Dis ease and Risk Management: Standards of Medical Care in Diabetes\u20142024. Diabetes Care 2024; 47 (Supplement 1): S219\u2013S230 https:\/\/doi.org\/10.2337\/dc24-S011","DOI":"10.2337\/dc24-S011"},{"key":"3985_CR32","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","volume":"27","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27:1954\u201360. https:\/\/doi.org\/10.1038\/s41591-021-01536-x.","journal-title":"Nat Med"},{"key":"3985_CR33","doi-asserted-by":"publisher","unstructured":"Indranil Dasgupta S, Zac-Varghese K, Chaudhry K, McCafferty P, Winocour TA, Chowdhury S, Bellary G, Goldet M, Wahba P, De AH, Frankel RM, Montero. Eirini Lioudaki, Debasish Banerjee, Ritwika Mallik, Adnan Sharif, Naresh Kanumilli, Nicola Milne, Dipesh C. Patel, Ketan Dhatariya, Stephen C. Bain, Janaka Karalliedde Current management of chronic kidney disease in type-2 diabetes\u2014A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) guidelines. First published: 17 October 2024 https:\/\/doi.org\/10.1111\/dme.15450","DOI":"10.1111\/dme.15450"},{"key":"3985_CR34","first-page":"4","volume":"20","author":"LQ He","year":"2021","unstructured":"He LQ. Dietary patterns and CKD risk: a systematic review and update meta-analysis of observational studies. Nutr J 2021. 2021;20:4.","journal-title":"Nutr J 2021"},{"key":"3985_CR35","doi-asserted-by":"crossref","unstructured":"Kelly JT. 2017 healthy dietary patterns and risk of mortality in ESRD in CKD: a meta-analysis of cohort studies. Clin J Am Soc Nephrol. 12 272\u20139.","DOI":"10.2215\/CJN.06190616"},{"key":"3985_CR36","first-page":"S6","volume":"33","author":"K Sumida","year":"2023","unstructured":"Sumida K. New insights into dietary approaches to potassium management in CKD. JRN. 2023;33:S6\u201312.","journal-title":"JRN"},{"key":"3985_CR37","unstructured":"National Institute for Health and Care Excellence. Patiromer for treating hyperkalaemia. NICE Technology Appraisal guidance: TA623 Published: 13 February 2020 www.nice.org.uk\/guidance\/ta623"},{"key":"3985_CR38","unstructured":"National Institute for Health and Care Excellence. Sodium zirconium cyclosilicate for treating hyperkalaemia. NICE Technology Appraisal guidance, reference number: TA599 published: 04 September 2019, last updated: 24 January 2022 www.nice.org.uk\/guidance\/ta599"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-03985-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-03985-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-03985-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T15:18:26Z","timestamp":1739027906000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-03985-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,8]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3985"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-03985-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,8]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This document was reviewed across the entire membership of the guideline group which is a joint committee of both the Association of British Clinical Diabetologist (ABCD) and UK Kidney Association (UKKA).AF has attended drug advisory boards of Boehringer Ingleheim, AstraZeneca, NAPP, Novo Nordisk, MSD, VP UK.PW has received honoraria for delivering educational meetings and\/or attending advisory boards for Abbott, Astra Zeneca, Bayer, Boehringer Ingleheim, Eli Lilly, MSD, NAPP, Sanofi, Novo and Vifor Pharmaceuticals.SCB reported receiving personal fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk and Sanofi-Aventis (honoraria); Medscape (funding for the development of educational programmes); All Wales Medicines Strategy Group and National Institute for Health and Care Excellence UK (providing expert advice) and is a shareholder of Glycosmedia.SB has received speaker fees and support to attend educational meetings from AstraZeneca, Novo Nordisk, Eli Lilly and Boehringer Ingelheim.PD has received honoraria for educational meetings from AstraZeneca, Janssen, Boehringer Ingelheim, Novo, Sanofi, Novartis, Abbott, MSD, Takeda, Roche, Lilly, Ascensia, BD, Internis, GSK, Menarini, Daichi-Sankyo, Bayer and Besins.DB has received grant from AstraZeneca and speaker fees from Vifor Pharma.JK has received honoraria for delivering educational meetings and\/or attending advisory boards from Boehringer Ingelheim, AstraZeneca, Sanofi, NAPP and research grants from AstraZeneca and Sanofi.ID is chief investigator in the UK for three GSK sponsored trials and has chaired GSK advisory board. He has received a research grant from Sanofi Genzyme.Other authors have declared no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"63"}}